These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11255279)

  • 1. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients.
    Dotti G; Gaspari F; Caruso R; Perico N; Remuzzi G; Barbui T; Rambaldi A
    Haematologica; 2001 Mar; 86(3):311-5. PubMed ID: 11255279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
    Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients.
    Parquet N; Reigneau O; Humbert H; Guignard M; Ribaud P; Socié G; Devergie A; Espérou H; Gluckman E
    Bone Marrow Transplant; 2000 May; 25(9):965-8. PubMed ID: 10800064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.
    Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R
    Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
    van Mourik ID; Thomson M; Kelly DA
    Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients.
    Leet A; Richardson M; Senior JA; Funston R; Skiba M; Bailey M; Krum H
    J Heart Lung Transplant; 2009 Sep; 28(9):894-8. PubMed ID: 19716041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
    Carstens J
    Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F; Gonzalez L; Trull AK
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation.
    Kesten S; Scavuzzo M; Chaparro C; Szalai JP
    Pharmacotherapy; 1998; 18(4):847-50. PubMed ID: 9692659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients.
    Sagedal S; Asberg A; Hartmann A; Bergan S; Berg KJ
    Clin Transplant; 1998 Dec; 12(6):553-6. PubMed ID: 9850449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions.
    Knoop C; Vervier I; Thiry P; De Backer M; Kovarik JM; Rousseau A; Marquet P; Estenne M
    Transplantation; 2003 Aug; 76(4):683-8. PubMed ID: 12973109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.
    Kimura S; Oshima K; Okuda S; Sato K; Sato M; Terasako K; Nakasone H; Kako S; Yamazaki R; Tanaka Y; Tanihara A; Higuchi T; Nishida J; Kanda Y
    Bone Marrow Transplant; 2010 Jun; 45(6):1088-94. PubMed ID: 19898510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.